Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Associated With Chemo-induced Amenorrhea Between Docetaxel Plus Epirubicin, and Docetaxel Plus Epirubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients.

NCT01503905 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT01503905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01503905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Associated With Chemo-induced Amenorrhea Between Docetaxel Plus Epirubicin, and Docetaxel Plus Epirubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients.
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2011
Completion date
December 31, 2021
Enrollment
600 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer nos premenopausal